Gurpreet Singh

Gurpreet Singh

Auto-generated profile, based on publicly available information

Gurpreet Singh

Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KNKathryn M. Nelson
Kathryn M. Nelson
JBJonathan Bisson
Jonathan Bisson
GSGurpreet Singh
Gurpreet Singh
JGJames G. Graham
James G. Graham
SCShao-Nong Chen
Shao-Nong Chen
GPGuido F. Pauli
Guido F. Pauli

1 April 2025 in Circulation
Verified
Journal Article
Closed access
BZBin Zhang
Bin Zhang
MEMaurice Enriquez-Sarano
Maurice Enriquez-Sarano
HSHartzell Vernon Schaff
Hartzell Vernon Schaff
HMHector I. Michelena
Hector I. Michelena
CRCarolyn M. Roos
Carolyn M. Roos
JMJordan D. Miller
Jordan D. Miller
BACKGROUND: Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years. Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS. METHODS: We used quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry to characterize sGC signaling and the biological effects of ataciguat on signaling cascades related to nitric oxide, calcification, and fibrosis in excised human aortic valve tissue, aortic valve interstitial cells, and mouse aortic valves. We then conducted randomized, placebo-controlled phase I (14-day safety/tolerance) and phase II (6-month efficacy) trials in patients with moderate aortic valve stenosis. RESULTS: In excised human tissue, we found robust losses in sGC signaling despite upregulation of sGC subunits. In vitro, ataciguat increased sGC signaling and reduced BMP2 (bone morphogenetic protein 2) signaling in aortic valve interstitial cells. In mice with established FCAVS, treatment with ataciguat attenuated BMP signaling and slowed progression of valve calcification and dysfunction. In a phase I, randomized, placebo-controlled trial, treatment with ataciguat for 2 weeks was safe and well tolerated in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02049203). In a separate phase II, randomized, placebo-controlled trial, treatment with ataciguat for 6 months slowed the progression of aortic valve calcification and tended to slow the progression of valvular and ventricular dysfunction in patients with moderate FCAVS ( https://www.clinicaltrials.gov ; Unique identifier: NCT02481258). CONCLUSIONS: Collectively, this study highlights the therapeutic potential of the targeted restoration of the diseased/inactive form of sGC for treatment of FCAVS. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02049203. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02481258.

5 January 2022 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
MBMerlin Bresinsky
Merlin Bresinsky
JSJessica M. Strasser
Jessica M. Strasser
BVBernadette Vallaster
Bernadette Vallaster
PLPeng Liu
Peng Liu
WMWilliam M. McCue
William M. McCue
SPSteffen Pockes
Steffen Pockes

6 May 2022 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
GSGurpreet Singh
Gurpreet Singh
PLPeng Liu
Peng Liu
KYKatherine R. Yao
Katherine R. Yao
JSJessica M. Strasser
Jessica M. Strasser
CHChris Hlynialuk
Chris Hlynialuk
SPSteffen Pockes
Steffen Pockes